drugset / Trial / NCT00168103

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

NCT00168103

Phase 2/3 Completed 126 enrolled CSL Behring
RandomizedParallel-groupDouble-blindTreatment

Summary

HAE is a rare disorder characterized by functional C1 esterase inhibitor deficiency. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of swelling of the larynx. This clinical Phase 2/Phase 3 study was designed to provide clinically relevant data on dosing, efficacy and safety in subjects with HAE.

Timeline

Start
2005-06
Primary completion
2007-10
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CINRYZE Protein / enzyme biologic 10 iu/kg Intravenous
Subject CINRYZE Protein / enzyme biologic 20 iu/kg Intravenous

Indications